State Street Corp Has $85.67 Million Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

State Street Corp decreased its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 3.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,690,274 shares of the biopharmaceutical company’s stock after selling 272,501 shares during the period. State Street Corp owned about 0.06% of Dynavax Technologies worth $85,670,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. SummerHaven Investment Management LLC grew its stake in shares of Dynavax Technologies by 2.4% in the 2nd quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 1,303 shares during the period. Louisiana State Employees Retirement System boosted its position in Dynavax Technologies by 3.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company’s stock valued at $740,000 after buying an additional 1,900 shares during the last quarter. AlphaCentric Advisors LLC boosted its position in Dynavax Technologies by 6.1% in the 2nd quarter. AlphaCentric Advisors LLC now owns 130,000 shares of the biopharmaceutical company’s stock valued at $1,460,000 after buying an additional 7,500 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Dynavax Technologies by 1.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 1,172 shares during the last quarter. Finally, Peregrine Capital Management LLC boosted its position in Dynavax Technologies by 1.3% in the 2nd quarter. Peregrine Capital Management LLC now owns 534,454 shares of the biopharmaceutical company’s stock valued at $6,002,000 after buying an additional 6,952 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

DVAX stock opened at $12.85 on Tuesday. The business’s fifty day moving average is $12.02 and its 200-day moving average is $11.48. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.69 billion, a P/E ratio of 100.00 and a beta of 1.33. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $15.01.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.